

GLAXOSMITHKLINE PLC
Form 6-K
January 17, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 16 January 2017

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- | | |
|---------------------------------------|----------------------|
| a) Name | Ms E Walmsley |
| b) Position/status | CEO Designate |
| c) Initial notification/
amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- | | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- | | | |
|--|---|-----------|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |
| b) Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme. | |
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | £15.7075 | 489.079 |

- | | |
|---------------------------|--------------------------|
| d) Aggregated information | n/a (single transaction) |
|---------------------------|--------------------------|

- | | |
|-----------------------------|------------|
| e) Date of the transaction | 2017-01-12 |
| f) Place of the transaction | n/a |

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
- b) Position/status President, Global Manufacturing & Supply
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on Ordinary Shares held in the Company's Deferred Investment Award Programme.
- c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7075	195.631
- d) Aggregated information n/a (single transaction)
Aggregated volume Price
- e) Date of the transaction 2017-01-12
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S A Hussain
- b) Position/status

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

President, Global
Pharmaceuticals

- c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence
each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest
in Ordinary Shares following
the re-investment of
dividends paid to
shareholders on 12 January
2017 on Ordinary Shares held
in the Company's Deferred
Investment Award
Programme.
- | c) Price(s) and volume(s) | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| | £15.7075 | 244.539 |
- d) Aggregated information n/a (single transaction)
- Aggregated volume Price
- e) Date of the transaction 2017-01-12
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr B McNamara
- b) Position/status CEO, GSK Consumer
Healthcare
- c) Initial notification/
amendment Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument GlaxoSmithKline plc
American Depositary Shares ('ADSs')
ISIN: US37733W1053

- b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's Deferred Investment Award Programme.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
\$38.9750	307.510

- d) Aggregated information n/a (single transaction)
- Aggregated volume Price

- e) Date of the transaction 2017-01-12

- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D S Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.7075	195.631
d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2017-01-12	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms C Thomas
b) Position/status	Senior Vice President, Human Resources
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.7075	195.631
d) Aggregated information	n/a (single transaction)	
Aggregated volume Price		
e) Date of the transaction	2017-01-12	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Dr P J T Vallance
b) Position/status	President, R&D
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	
--	--

Ordinary shares of 25 pence
each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.7075	244.539
d) Aggregated information Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2017-01-12	
f) Place of the transaction	n/a	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: January 16, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc